Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mirikizumab PFS vs Autoinjector
NCT05069896Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 2040 hours, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at 2040 hours and 1 more. Started Oct 2021; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05069896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069896.